Information from Industry - Sponsored Supplement
“The Nail in the Coffin for Fibrates”: Futility of PROMINENT Trial Definitively Settles Debate on Avoiding Use of Fibrate Class of Medications for Cardiovascular Risk Reduction
Developed under the direction and sponsorship of Amarin Pharma, Inc. This content was prepared by the specialized content division of FMC of Cardiology News.
January 3, 2023|Cardiology
In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction.
,